Table 1.
Target | Compound | Mode of action | Clinical potential | Reference |
---|---|---|---|---|
End stage of autophagy | HCQ | Autophagolysosome formation | Autophagy inhibition | 42, 55 |
Lyso 5 | Autophagolysosome formation | Autophagy inhibition | 57 | |
Vacuolar H+-ATPase | Bafilomycin A1 | Deacidification | H+-ATPase inhibition | 62 |
Archazolid | Deacidification | H+-ATPase inhibition | 64 | |
Cleistanthin A | Deacidification | H+-ATPase inhibition | 65 | |
Manzamine A | Deacidification | H+-ATPase inhibition | 66 | |
ASM | Cationic amphiphilic drugs | Modulate ASM metabolism | ASM modulator | 77 |
Lysosomal hydrolases | Pepstatin | Inhibition of cathepsin D | Acid protease inhibitor | 68 |
CA-074 | Inhibition of cathepsin B | Acid protease inhibitor | 69 | |
Z-FF-FMK | Inhibition of cathepsin L | Acid protease inhibitor | 72 | |
Cat S/6n | Inhibition of cathepsin S | Acid protease inhibitor | 71 | |
HPS70 | PES | ASM metabolism, LMP | ASM modulator | 76 |